A retrospective clinical study examining a large cohort of tamoxifen treated, ER + breast cancer patients found that the patients with co-expression of erbB2 and erbB3 were significantly more likely to relapse on tamoxifen [66]. This evidence concerns the gene ERBB2 and breast cancer.